<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Inhibitor of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> proteins (IAPs) are upregulated in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> and suppress cell <z:hpo ids='HP_0011420'>death</z:hpo>, in part, through their ability to directly inhibit caspases </plain></SENT>
<SENT sid="1" pm="."><plain>Inhibitor of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> proteins are differentially expressed in B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The functions of some IAPs are counteracted by the cell <z:hpo ids='HP_0011420'>death</z:hpo> inducer, second <z:hpo ids='HP_0001427'>mitochondrial</z:hpo>-derived activator of caspases/direct IAP binding protein with low pI (Smac/DIABLO) </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, we investigated the expression levels of Smac/DIABLO in 14 <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines by Western blot analysis </plain></SENT>
<SENT sid="4" pm="."><plain>We also assessed 247 B-cell non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) and 40 Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> using immunohistochemical methods </plain></SENT>
<SENT sid="5" pm="."><plain>Smac/DIABLO was expressed in most NHL and <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> cell lines </plain></SENT>
<SENT sid="6" pm="."><plain>In NHL, Smac/DIABLO was expressed in 117 (47%) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and was differentially expressed in various NHL types </plain></SENT>
<SENT sid="7" pm="."><plain>In most NHLs, from 29% to 68% of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were positive; however, Smac/DIABLO was not detected in small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> and Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and was rare in extranodal marginal zone B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>In <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>, Smac/DIABLO was positive in 25 (63%) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Unlike NHL, <z:hpo ids='HP_0000001'>all</z:hpo> types of <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> were positive for Smac/DIABLO, although nodular <z:mp ids='MP_0000612'>sclerosis</z:mp> was least often positive </plain></SENT>
<SENT sid="10" pm="."><plain>The differential expression of Smac/DIABLO in NHLs suggests that apoptotic mechanisms are differentially involved in their pathogenesis </plain></SENT>
<SENT sid="11" pm="."><plain>These results may also have implications for using Smac/DIABLO or its <z:chebi fb="4" ids="48705">agonists</z:chebi> as therapeutic agents </plain></SENT>
</text></document>